1. Home
  2. CISS vs PFSA Comparison

CISS vs PFSA Comparison

Compare CISS & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$2.44

Market Cap

1.9M

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$0.37

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISS
PFSA
Founded
2022
2009
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
2.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CISS
PFSA
Price
$2.44
$0.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
437.6K
Earning Date
05-19-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.05
52 Week High
$6.06
$4.22

Technical Indicators

Market Signals
Indicator
CISS
PFSA
Relative Strength Index (RSI) 47.28 36.11
Support Level $2.04 $0.28
Resistance Level $2.81 $0.41
Average True Range (ATR) 0.41 0.04
MACD -0.17 0.00
Stochastic Oscillator 1.89 9.25

Price Performance

Historical Comparison
CISS
PFSA

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: